Gedeon Richter expects 2-3% increase in sales revenues in 2019
…royalties in excess of $1bn. There is further potential in the product, as its scope could be expanded – the US Food and Drug Administration (FDA) is, at, present reviewing the application submitted by Gedeon Richter’s partner, Allergan, to approve it for bipolar depression.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)